KR102748684B1 - 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법 - Google Patents

술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법 Download PDF

Info

Publication number
KR102748684B1
KR102748684B1 KR1020217042364A KR20217042364A KR102748684B1 KR 102748684 B1 KR102748684 B1 KR 102748684B1 KR 1020217042364 A KR1020217042364 A KR 1020217042364A KR 20217042364 A KR20217042364 A KR 20217042364A KR 102748684 B1 KR102748684 B1 KR 102748684B1
Authority
KR
South Korea
Prior art keywords
group
substituted
atom
cancer
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217042364A
Other languages
English (en)
Korean (ko)
Other versions
KR20220015430A (ko
Inventor
히로유키 우에노
사야카 츠키오카
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20220015430A publication Critical patent/KR20220015430A/ko
Application granted granted Critical
Publication of KR102748684B1 publication Critical patent/KR102748684B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217042364A 2019-05-29 2020-05-28 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법 Active KR102748684B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019100136 2019-05-29
JPJP-P-2019-100136 2019-05-29
PCT/JP2020/021108 WO2020241749A1 (ja) 2019-05-29 2020-05-28 スルホンアミド化合物と免疫調節剤を用いるがん併用療法

Publications (2)

Publication Number Publication Date
KR20220015430A KR20220015430A (ko) 2022-02-08
KR102748684B1 true KR102748684B1 (ko) 2025-01-02

Family

ID=73553795

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042364A Active KR102748684B1 (ko) 2019-05-29 2020-05-28 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법

Country Status (8)

Country Link
US (1) US20220226291A1 (https=)
EP (1) EP3978017A4 (https=)
JP (1) JP7179174B2 (https=)
KR (1) KR102748684B1 (https=)
AU (1) AU2020283299B2 (https=)
MA (1) MA56065A (https=)
TW (1) TWI781405B (https=)
WO (1) WO2020241749A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240158383A1 (en) * 2021-03-02 2024-05-16 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof
IL311458A (en) * 2021-09-17 2024-05-01 Boundless Bio Inc Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4402134A4 (en) * 2021-09-17 2025-10-15 Boundless Bio Inc SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND THEIR USES
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017209155A1 (ja) 2016-05-31 2017-12-07 大鵬薬品工業株式会社 スルホンアミド化合物又はその塩

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
AU2015203322B2 (en) * 2009-07-20 2016-09-29 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP3099717B1 (en) * 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
JP7023690B2 (ja) 2017-12-06 2022-02-22 株式会社東芝 道路維持管理システム、道路維持管理方法及びコンピュータプログラム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017209155A1 (ja) 2016-05-31 2017-12-07 大鵬薬品工業株式会社 スルホンアミド化合物又はその塩

Also Published As

Publication number Publication date
EP3978017A1 (en) 2022-04-06
MA56065A (fr) 2022-04-06
KR20220015430A (ko) 2022-02-08
US20220226291A1 (en) 2022-07-21
TW202110442A (zh) 2021-03-16
TWI781405B (zh) 2022-10-21
AU2020283299B2 (en) 2024-08-01
JPWO2020241749A1 (https=) 2020-12-03
WO2020241749A1 (ja) 2020-12-03
EP3978017A4 (en) 2023-06-28
JP7179174B2 (ja) 2022-11-28
AU2020283299A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
KR102748684B1 (ko) 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
KR101950044B1 (ko) Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법
EP3421039B1 (en) Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
JP6757959B2 (ja) 抗がん剤
JP6751212B2 (ja) 抗腫瘍剤
US20250170108A1 (en) Chemotherapy for cancer using azabicyclo compound
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
EP4209216A1 (en) Pharmaceutical composition for treating tumors
JP2021513512A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
WO2022084930A2 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
RU2820817C2 (ru) Комбинированное лечение злокачественного новообразования с использованием сульфонамидного соединения и иммунорегулятора
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
JPWO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
CN117377471A (zh) 治疗肿瘤的联合疗法
JP7816164B2 (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
JP2026067904A (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
BR112019028226B1 (pt) Agente antitumoral que compreende um composto azabiciclo em combinação com um regulador da molécula de checkpoint imunológico, agente potencializador de efeito antitumoral para o dito regulador, imunoestimulante e usos dos ditos composto e regulador para tratar câncer
BR122025010361A2 (pt) Agente antitumoral compreendendo um composto azabiciclo em combinação com um regulador da molécula de checkpoint imunológico, agente potencializador de efeito antitumoral para o dito regulador, imunoestimulante e usos dos ditos composto e regulador
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20211224

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211224

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231221

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241118

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241204

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
PG1601 Publication of registration